Introduction
Sinonasal malignancies (SNMs) are rare, comprising 1 to 3% of all head and neck malignancies.
1,2 They are characterized by poor prognosis and histopathological heterogeneity. There are a wide variety of tumors that arise within the sinonasal cavity, including squamous cell carcinoma, adenocarcinoma, neuroendocrine carcinoma, and melanoma. 3, 4 The most frequently involved anatomical sites are the nasal cavity and maxillary sinus. 4 Patients with SNM typically present with nonspecific symptoms and late stage disease by the time of diagnosis. 5 Due to this delay in diagnosis, there is usually extensive involvement of adjacent structures, resulting in poor prognosis with an overall 5-year survival rate of 30 to 50%. 4, 6, 7 Additionally, local recurrence is common within 2 years after treatment and serves as the main cause of poor outcome and mortality.
8,9
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Abstract
Objective To investigate the incidence and degree of contralateral sinus disease following treatment of sinonasal malignancy (SNM) using radiological findings as an outcome measure. Study Design Retrospective case series. Setting Tertiary referral academic center.
Participants Patients with SNM treated with surgical and adjuvant radiotherapy with or without concurrent chemotherapy.
Main Outcome Measures Pre-and posttreatment computed tomography and magnetic resonance imaging scans, Lund-Mackay (LM) score, date of diagnosis, chemotherapy, and dosage of radiation therapy (RT).
Results There was a significant difference between pre-and posttreatment LM scores (p < 0.001) of the contralateral paranasal sinuses. There was no statistical significance between the change in pre-and posttreatment LM scores and patient age, gender, chemotherapy, RT dosage, and time lapse between diagnosis and when we performed this study in the univariate and the multivariable analyses.
Conclusions Following treatment of SNM with surgical resection and RT, there was a significant increase in incidence and degree of mucosal thickening of the contralateral sinus by LM grading that persisted after the completion of treatment. This indicates the need for long-term follow-up to monitor for chronic rhinosinusitis as a delayed complication following treatment of SNM.
Complete resection, through open or endoscopic approach, followed by postoperative radiotherapy is the mainstay of SNM management. 7 Recently published survival data has demonstrated that radical resection can often be achieved endoscopically with adequate exposure and margins when compared with traditional open surgical approaches. [10] [11] [12] While radiotherapy to the sinonasal cavity is challenging due to the potential toxicity to the surrounding structures, such as the optic architecture and brain, novel techniques show promise in limiting radiation exposure to adjacent normal tissue. Intensity-modulated radiation therapy (IMRT), volumetric-modulated arc therapy (VMAT), and proton beam therapy allow for delivery of high doses to the target volume with steep dose falloff immediately outside these regions, minimizing toxicity to surrounding structures.
7,10,13
We and others have found that complications from treatment, such as wound infections, cerebrospinal fluid (CSF) leak, and meningitis, can occur immediately posttreatment or in a delayed fashion, including issues with wound healing and nasocutaneous fistula.
14-17 Late radiation-induced toxicities include several ophthalmic conditions such as dry eye, epiphora, retinopathy, and optic neuropathy. We and others have also shown that postradiation chronic rhinosinusitis (CRS) has been found to be a delayed complication of radiotherapy for SNM. [10] [11] [12] As expected, the development of CRS after treatment of SNM is most commonly ipsilateral to the malignancy, where there has been surgical intervention and the majority of the radiation dose was focused. 11 However, little has been described about the effects of radiation and development of CRS in the contralateral paranasal sinuses following treatment for SNM. The purpose of this study was to investigate the development of contralateral sinus disease on radiographic imaging following treatment for SNM. 
Materials and Methods

Patient Selection
Measures of Sinonasal Disease
Imaging of the contralateral uninvolved sinuses was scored using the Lund-Mackay (LM) staging system (►Fig. 1-3).
18
Each paranasal sinus (anterior ethmoid, posterior ethmoid, maxillary, frontal, and sphenoid) was assigned a score of 0 for no abnormality, 1 for partial opacification, or 2 for total opacification. The osteomeatal unit was assigned a score of 0 for patency or 2 for obstruction. As previously described, in patients with surgically resected sinus cavities (e.g., frontal sinus exenteration), an adjusted LM score was calculated by multiplying the raw LM score by 6/n, the total number of unilateral sinuses divided by n, where n represents the actual number of sinuses (including the osteomeatal complex [OMC]) present (►Table 1).
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Statistical Analysis
The incidence of mucosal thickening was calculated. Descriptive statistics including mean, median, and standard deviation (SD) were determined. Differences in pre-and posttreatment LM scores in each sinus and the total score were analyzed with the Mann-Whitney U test. Univariate and multivariable linear regressions were performed between the change in pre-and posttreatment LM scores (as the dependent variables) with age, gender, pretreatment LM score, chemotherapy, radiation dosage, and time lapse between diagnosis and time of study (as independent variables). Significance was determined with a p-value of less than 0.05. 
Results
A total of 36 cases of SNM were identified who met inclusion criteria. Of them, 19 were male (52.8%) and 17 were female (47.2%) (p ¼ 0.43). Mean age was 54.6 years (median: 57.5; range: 15-85 years). The primary tumor sites were identified as the nasal cavity (n ¼ 17; 50%), maxillary sinus (n ¼ 12; 33.3%), ethmoid sinus (n ¼ 6; 16.7%), and sphenoid sinus (n ¼ 1; 2.8%). The majority of tumors were squamous cell carcinoma (n ¼ 17; 47.2%). Additionally, eight (22.2%) tumors were esthesioneuroblastoma, four (10%) tumors were sinonasal undifferentiated carcinoma, two (5.6%) melanoma, two (5.6%) adenocarcinoma, one (2.8%) adenoid cystic carcinoma, one (2.8%) fibrosarcoma, and one (2.8%) osteosarcoma (►Table 2). All patients underwent surgical resection followed by RT and 55.6% of patients received adjuvant chemotherapy. Of the 36 patients, all but 2 received a platinum-containing chemotherapy drug (cisplatin or carboplatin), either alone or in combination with etoposide, cetuximab, or paclitaxel. Patients received either IMRT (n ¼ 12; 33.3%), proton beam RT (n ¼ 19; 52.8%), or a combination of proton beam and photon RT (n ¼ 4; 11.1%). The type of RT was not available for one patient. The median total dose delivered to the primary site was 66.55 cobalt gray equivalent (range: 54-76; SD ¼ 5.0). Posttreatment scans were obtained at a mean of 8 months (SD AE 4.34; median: 6.5 months; range: 3-21 months) following completion of radiotherapy. Prior to treatment, the mean LM score of the contralateral paranasal sinuses was 2.52 AE 2.4. Posttreatment, mean LM score of the contralateral sinuses was 5.21 AE 3.5 (►Table 3). The mean difference between pre-and posttreatment LM scores of the contralateral sinuses was 2.7 AE 2.8 (p < 0.001). Among the individual contralateral sinuses, there was a significant increase in mean LM score in the maxillary (p < 0.01) and frontal sinuses (p ¼ 0.04) and the OMC (p ¼ 0.01). The incidences of mucosal thickening pre-and posttreatment are shown in ►Table 3. The anterior ethmoid (61%) and posterior ethmoid sinuses (41.6%) were the most common contralateral sites of pre-RT mucosal thickening. Following RT treatment, the most common contralateral sites of mucosal thickening were the anterior ethmoid (82.3%) and maxillary sinuses (66.7%). There was significant increase in the incidence of mucosal thickening in the maxillary sinus (p ¼ 0.01), OMC (p ¼ 0.01), and the overall total incidence of mucosal thickening on the contralateral side (p < 0.01) (►Table 3).
In the univariate linear regression analysis, there was no association between the change in contralateral LM score and the pretreatment LM score, age, gender, chemotherapy, RT dosage, and time lapse between diagnosis and time of study (months) (►Table 4).
In the multivariable analysis, there was no association between the change in contralateral LM scores and pretreatment LM score, age, gender, chemotherapy, RT dosage, and time lapse from diagnosis to time of study (months) (►Table 4).
Discussion
SNM are rare and usually present as locally advanced disease due to delay in diagnosis. The accommodating nature of the sinonasal cavity allows for expansile growth, and together with the vague presenting symptoms, which are often associated with benign sinonasal disease, these tumors are frequently diagnosed in the advanced stage.
12,19 These malignancies have heterogeneous histological characteristics and within the tumor may show variable degrees of differentiation. 19 In addition to this, the complexity of the sinonasal anatomy and proximity to critical structures make treatment planning complex. While open craniofacial resection remains the gold standard for resection of SNM involving the anterior skull base, endoscopic resection has proven to have comparable survival results in recent studies.
14-16
Survival and prognosis have improved with the advancement in surgical resection and reconstruction, and also with changes to adjuvant radiotherapy, including IMRT, VMAT, and proton and heavy ion therapy, which enables welldefined target volumes and steep dose gradients to minimize exposure to the surrounding structures. 17 Proton beam therapy is beneficial for SNM because it deposits nearly all of the energy at the point of greatest penetration with no exit dose; therefore, normal tissue beyond the target receive little or no radiation. 20 Neoadjuvant chemotherapy, usually cisplatin with either 5-fluorouracil, taxane, ifosfamide, or vincristine, improves locoregional control and distant metastasis for certain malignancies. 19 Based on current studies, multimodality therapy is beneficial in the treatment of SNM, improving outcomes and survival. We have previously described the development and management of CRS as a delayed complication of radiotherapy for treatment of SNM.
12 Because radiation-induced CRS is not lifethreatening, it is likely underreported as a complication and therefore deserves greater awareness by clinical providers of patients with SNM. In this study, we evaluated the development of radiographic changes in the contralateral paranasal sinuses after definitive treatment for SNM, including radiotherapy, and have found an increased incidence of mucosal thickening in the contralateral sinuses after treatment.
Complications of radiotherapy are well-documented. Short-term follow-up of treatment complications is typically focused on ocular, intracranial, and wound issues, and the rarity of SNM limits large cohort studies. 21 In one review of esthesioneuroblastoma management with proton beam therapy, 36% of patients were found to have eye and optical axis complications, 9% were reported to have CSF leak and pneumocephalus, and 36% were found to have wound healing issues. In another report on IMRT, acute and late radiation toxicity was described. 20 Mucositis (97.6%) was the most common acute complication, and late toxicity affected the mucous membranes in 73.7%, with all toxicities being mild.
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However, mucous membrane toxicity specific to the sinonasal cavity and CRS was never specifically described in either of these studies. The toxic effects of radiation on the paranasal sinus mucosa are well-documented and include ciliary loss and dysfunction and disruption of the mucociliary bed by reduced glandular activity and increase in production of collagenous fibrous tissue. 22, 23 Histopathological changes due to RT have been found to have radiological correlates. 23 In the nasopharyngeal carcinoma literature, mucosal thickening can be observed within the first 3 months after treatment with progression of severity over the first 30 months after treatment, with significantly increased LM scores at all posttreatment time points. 23 Previous work has shown that patients treated for SNM can result in clinically significant CRS affecting the ipsilateral sinuses. 12 Furthermore, upon evaluation of mucosal thickening in the contralateral paranasal sinus, Wang et al found a significant increase in the LM score at 3 months in those patients who were treated with surgery and RT compared with patients who were treated with surgery alone for sinonasal carcinoma. 24 Although mucosal thickening is not diagnostic of CRS, correlation studies have shown good sensitivity and above-average specificity in the diagnosis of CRS.
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In our study, we evaluated the development of radiographic mucosal thickening in the contralateral paranasal sinus cavity after treatment of SNM with surgery and radiotherapy. We found a significant increase in mucosal thickening, as reflected by an increase in the LM score from 2.52 to 5.21, in the contralateral paranasal sinus cavities between pre-and posttreatment imaging. There was also an increase in incidence of mucosal thickening from 30.6% in the contralateral paranasal sinuses prior to treatment to 86.1% posttreatment. There was no association between mucosal thickening when compared with age, gender, chemotherapy status, and radiation dosage. Additionally, there was no association between change in contralateral LM score and time lapse from date of diagnosis to time of this study, implying that there was no difference in development of long-term complications based on technological advances in radiation treatment modalities over time. Theoretically, proton beam therapy has less toxicity because it delivers all of its energy at the point of greatest penetration, unlike external beam photons, which deliver their highest dose at the skin. 20 Despite focused delivery of proton beam therapy and IMRT to the target site of the SNM with limited spread of radiation, there were still significant changes in the sinonasal cavity of the contralateral side. In our study of SNM, we found the highest incidence of contralateral mucosal thickening and greatest LM score in the anterior ethmoid sinuses posttreatment. The contralateral maxillary sinus also had a significant increase in mucosal thickening posttreatment compared with pretreatment. This development of mucosal thickening on the contralateral side posttreatment highlights the importance and necessity of routine sinus evaluation and care in this patient population. The possibility of CRS as a delayed complication following SNM treatment must be considered to improve our understanding of this toxicity. In addition, appropriate counseling and follow-up care must be provided for patients.
Our study should be interpreted within the constraints of its limitations such as the retrospective design of this study. Additionally, we used a radiological grading system to assess the paranasal sinuses of our SNM cohort and radiographic changes are nonspecific for the diagnosis of CRS, and therefore we cannot directly correlate these findings to the clinical diagnosis of CRS. The imaging of our cohort was scored using a mix of CT and MRI imaging, which could affect the overall score as MRI is more sensitive to detecting mucosal thickening. 26 The extent of surgical resection was highly variable in this cohort and there is a possibility that the type of surgery employed might have an effect on the development of contralateral sinonasal mucosal thickening. We did not assess the association between type of surgical resection and mucosal thickening because of the small size of this patient group. The type of RT may also affect incidence of acute and late toxicities; however, we did not specifically assess the association between type of RT and mucosal thickening because of the small cohort size. Despite these constraints, our results suggest that increased screening of irradiated SNM patients for CRS through close clinical followup including endoscopic examination and symptom assessment may be a simple way to ensure that these patients receive the appropriate sinonasal care. Finally, we did not study radiographic changes in the paranasal sinuses ipsilateral to the SNM. As we have described previously, previous studies have already shown that ipsilateral development of CRS occurs after radiation treatment of SNM. Further work is nonetheless necessary to correlate symptoms with radiological findings as well as to assess persistence of ipsilateral and contralateral mucosal disease long-term.
Conclusion
Following treatment of SNM with surgical resection and adjuvant RT, there is a significant increase in incidence and degree of mucosal thickening in the contralateral paranasal sinus cavities by LM grading that persists following the completion of treatment. This underscores the importance of long-term follow-up and monitoring for CRS following treatment of SNM, even in the age of targeted radiotherapy.
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